A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to a 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients
Phase of Trial: Phase IV
Latest Information Update: 16 May 2017
At a glance
- Drugs Cabozantinib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- Acronyms EXAMINER
- Sponsors Exelixis
- 27 Mar 2015 New source identified and integrated (European Clinical Trials Database record:2013-003402-40)
- 23 Jan 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
- 14 Dec 2014 Planned number of patients changed from 112 to 188 as reported by ClinicalTrials.gov record.